Development of conformation independent computational models for the early recognition of breast cancer resistance protein substrates

BioMed Research International

Volumn 2013, Issue , 2013, Pages

  Gantner, Melisa Edith ^a   Di Ianni, Mauricio Emiliano ^a   Ruiz, María Esperanza ^a   Talevi, Alan ^a   Bruno Blanch, Luis E ^a  

^a UNIVERSIDAD NACIONAL DE LA PLATA   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; LIGAND; ABC TRANSPORTER; ABCG2 PROTEIN, HUMAN; TUMOR PROTEIN;

ARTICLE; CONTROLLED STUDY; DISCRIMINANT ANALYSIS; LEARNING ALGORITHM; MATHEMATICAL MODEL; MATHEMATICAL PARAMETERS; MEASUREMENT ACCURACY; MOLECULAR RECOGNITION; PROTEIN ANALYSIS; PROTEIN CONFORMATION; PROTEIN DATABASE; RECEIVER OPERATING CHARACTERISTIC; BREAST TUMOR; CHEMICAL STRUCTURE; CHEMISTRY; DRUG RESISTANCE; ENZYME SPECIFICITY; FEMALE; HUMAN; METABOLISM;

ATP-BINDING CASSETTE TRANSPORTERS; BREAST NEOPLASMS; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MODELS, MOLECULAR; NEOPLASM PROTEINS; ROC CURVE; SUBSTRATE SPECIFICITY;

EID: 84883152604     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2013/863592     Document Type: Article

References (69)

1. Chan L. M. S., Lowes S., Hirst B. H., The ABCs of drug transport in intestine and liver: efflux proteins limiting drug absorption and bioavailability. European Journal of Pharmaceutical Sciences 2004 21 1 25 51 2-s2.0-0346728729 10.1016/j.ejps.2003.07.003
2. Dietrich C. G., Geier A., Oude Elferink R. P. J., ABC of oral bioavailability: transporters as gatekeepers in the gut. Gut 2003 52 12 1788 1795 2-s2.0-0344665555 10.1136/gut.52.12.1788
3. Potschka H., Role of CNS efflux drug transporters in antiepileptic drug delivery: overcoming CNS efflux drug transport. Advanced Drug Delivery Reviews 2012 64 943 952 2-s2.0-84858611805 10.1016/j.addr.2011.12.007
4. Chen Z.-S., Tiwari A. K., Multidrug resistance proteins (MRPs/ABCCs) in cancer chemotherapy and genetic diseases. FEBS Journal 2011 278 18 3226 3245 2-s2.0-80052449326 10.1111/j.1742-4658.2011.08235.x
5. Tiwari A. K., Sodani K., Dai C.-L., Ashby C. R. Jr., Che Z.-S., Revisiting the ABCs of multidrug resistance in cancer chemotherapy. Current Pharmaceutical Biotechnology 2011 12 4 570 594 2-s2.0-79953789525 10.2174/138920111795164048
6. Bauer B., Hartz A. M. S., Lucking J. R., Yang X., Pollack G. M., Miller D. S., Coordinated nuclear receptor regulation of the efflux transporter, Mrp2, and the phase-II metabolizing enzyme, GST π at the blood-brain barrier. Journal of Cerebral Blood Flow and Metabolism 2008 28 6 1222 1234 2-s2.0-44349163325 10.1038/jcbfm.2008.16
7. Burk O., Zie W., Nuclear receptor-mediated regulation of drug transporters. Nuclear Receptors in Drug Metabolism 2009 New York, NY, USA John Wiley & Sons
8. Englund G., Rorsman F., Rönnblom A., Karlbom U., Lazorova L., Gråsjö J., Kindmark A., Artursson P., Regional levels of drug transporters along the human intestinal tract: co-expression of ABC and SLC transporters and comparison with Caco-2 cells. European Journal of Pharmaceutical Sciences 2006 29 3-4 269 277 2-s2.0-33750181267 10.1016/j.ejps.2006.04.010
9. Hilgendorf C., Ahlin G., Seithel A., Artursson P., Ungell A.-L., Karlsson J., Expression of thirty-six drug transporter genes in human intestine, liver, kidney, and organotypic cell lines. Drug Metabolism and Disposition 2007 35 8 1333 1340 2-s2.0-34547169521 10.1124/dmd.107.014902
10. Tucker T. G. H. A., Milne A. M., Fournel-Gigleux S., Fenner K. S., Coughtrie M. W. H., Absolute immunoquantification of the expression of ABC transporters P-glycoprotein, breast cancer resistance protein and multidrug resistance-associated protein 2 in human liver and duodenum. Biochemical Pharmacology 2012 83 2 279 285 2-s2.0-83955163683 10.1016/j.bcp.2011.10.017
11. Dauchy S., Dutheil F., Weaver R. J., Chassoux F., Daumas-Duport C., Couraud P.-O., Scherrmann J.-M., De Waziers I., Declèves X., ABC transporters, cytochromes P450 and their main transcription factors: expression at the human blood-brain barrier. Journal of Neurochemistry 2008 107 6 1518 1528 2-s2.0-56749151204 10.1111/j.1471-4159.2008.05720.x
12. Shawahna R., Uchida Y., Declèves X., Ohtsuki S., Yousif S., Dauchy S., Jacob A., Chassoux F., Daumas-Duport C., Couraud P.-O., Terasaki T., Scherrmann J.-M., Transcriptomic and quantitative proteomic analysis of transporters and drug metabolizing enzymes in freshly isolated human brain microvessels. Molecular Pharmaceutics 2011 8 4 1332 1341 2-s2.0-79961096875 10.1021/mp200129p
13. Uchida Y., Ohtsuki S., Katsukura Y., Ikeda C., Suzuki T., Kamiie J., Terasaki T., Quantitative targeted absolute proteomics of human blood-brain barrier transporters and receptors. Journal of Neurochemistry 2011 117 2 333 345 2-s2.0-79953686193 10.1111/j.1471-4159.2011.07208.x
14. Deeken J. F., Löscher W., The blood-brain barrier and cancer: transporters, treatment, and trojan horses. Clinical Cancer Research 2007 13 6 1663 1674 2-s2.0-34250177984 10.1158/1078-0432.CCR-06-2854
15. Lhommé C., Joly F., Walker J. L., Lissoni A. A., Nicoletto M. O., Manikhas G. M., Baekelandt M. M. O., Gordon A. N., Fracasso P. M., Mietlowski W. L., Jones G. J., Dugan M. H., Phase III study of valspodar (PSC 833) combined with paclitaxel and carboplatin compared with paclitaxel and carboplatin alone in patients with stage IV or suboptimally debulked stage III epithelial ovarian cancer or primary peritoneal cancer. Journal of Clinical Oncology 2008 26 16 2674 2682 2-s2.0-45749089027 10.1200/JCO.2007.14.9807
16. Akhtar N., Ahad A., Khar R. K., Jaggi M., Aqil M., Iqbal Z., Ahmad F. J., Talegaonkar S., The emerging role of P-glycoprotein inhibitors in drug delivery: a patent review. Expert Opinion on Therapeutic Patents 2011 21 4 561 576 2-s2.0-79952903674 10.1517/13543776.2011.561784
17. Hartz A. M. S., Bauer B., Regulation of ABC transporters at the blood-brain barrier: new targets for CNS therapy. Molecular Interventions 2010 10 5 293 304 2-s2.0-78149477007 10.1124/mi.10.5.6
18. Milane L., Ganesh S., Shah S., Duan Z.-F., Amiji M., Multi-modal strategies for overcoming tumor drug resistance: hypoxia, the Warburg effect, stem cells, and multifunctional nanotechnology. Journal of Controlled Release 2011 155 2 237 247 2-s2.0-80054103346 10.1016/j.jconrel.2011.03.032
19. Begley D. J., ABC transporters and the blood-brain barrier. Current Pharmaceutical Design 2004 10 12 1295 1312 2-s2.0-1642454475 10.2174/1381612043384844
20. Ponte-Sucre A., Padrón-Nieves M., Díaz E., Ponte-Sucre A., ABC transporter blocker and reversal of drug resistance in microorganisms. ABC Transporters in Microorganisms. Research, Innovation and Value as Targets against Drug Resistance 2009 Norfolk, UK Caister Academic Press
21. Hazai E., Hazai I., Ragueneau-Majlessi I., Chung S. P., Bikadi Z., Mao Q., Predicting substrates of the human breast cancer resistance protein using a support vector machine method. BMC Bioinformatics 2013 14 130 10.1186/1471-2105-14-130
22. Zhong L., Ma C.-Y., Zhang H., Yang L.-J., Wan H.-L., Xie Q.-Q., Li L.-L., Yang S.-Y., A prediction model of substrates and non-substrates of breast cancer resistance protein (BCRP) developed by GA-CG-SVM method. Computers in Biology and Medicine 2011 41 11 1006 1013 2-s2.0-82655172381 10.1016/j.compbiomed.2011.08.009
23. Ecker G. F., Ecker G. F., Chiba P., QSAR studies on ABC transporter-How to deal with polyspecificity. Transporters as Drug Carriers 2009 Weinheim, Germany Wiley-VCH
24. Demel M. A., Krämer O., Ettmayer P., Haaksma E. E. J., Ecker G. F., Predicting ligand interactions with ABC transporters in ADME. Chemistry and Biodiversity 2009 6 11 1960 1969 2-s2.0-72449197501 10.1002/cbdv.200900138
25. Penzotti J. E., Lamb M. L., Evensen E., Grootenhuis P. D. J., A computational ensemble pharmacophore model for identifying substrates of P-glycoprotein. Journal of Medicinal Chemistry 2002 45 9 1737 1740 2-s2.0-0037171818 10.1021/jm0255062
26. Li W.-X., Li L., Eksterowicz J., Ling X. B., Cardozo M., Significance analysis and multiple pharmacophore models for differentiating P-glycoprotein substrates. Journal of Chemical Information and Modeling 2007 47 6 2429 2438 2-s2.0-37249060640 10.1021/ci700284p
27. Svetnik V., Wang T., Tong C., Liaw A., Sheridan R. P., Song Q., Boosting: an ensemble learning tool for compound classification and QSAR modeling. Journal of Chemical Information and Modeling 2005 45 3 786 799 2-s2.0-20444399504 10.1021/ci0500379
28. Cao D.-S., Huang J.-H., Yan J., Zhang L.-X., Hu Q.-N., Xu Q.-S., Liang Y.-Z., Kernel k-nearest neighbor algorithm as a flexible SAR modeling tool. Chemometrics and Intelligent Laboratory Systems 2012 114 19 23 2-s2.0-84860461316 10.1016/j.chemolab.2012.01.008
29. Giri N., Agarwal S., Shaik N., Pan G., Chen Y., Elmquist W. F., Substrate-dependent breast cancer resistance protein (Bcrp1/Abcg2)-mediated interactions: consideration of multiple binding sites in in vitro assay design. Drug Metabolism and Disposition 2009 37 3 560 570 2-s2.0-61449121173 10.1124/dmd.108.022046
30. Takenaka K., Morgan J. A., Scheffer G. L., Adachi M., Stewart C. F., Sun D., Leggas M., Ejendal K. F. K., Hrycyna C. A., Schuetz J. D., Substrate overlap between Mrp4 and Abcg2/Bcrp affects purine analogue drug cytotoxicity and tissue distribution. Cancer Research 2007 67 14 6965 6972 2-s2.0-34547114499 10.1158/0008-5472.CAN-06-4720
31. Hazai E., Bikádi Z., Homology modeling of breast cancer resistance protein (ABCG2). Journal of Structural Biology 2008 162 1 63 74 2-s2.0-41649122089 10.1016/j.jsb.2007.12.001
32. Allen J. D., Jackson S. C., Schinkel A. H., A mutation hot spot in the Bcrp1 (Abcg2) multidrug transporter in mouse cell lines selected for doxorubicin resistance. Cancer Research 2002 62 8 2294 2299 2-s2.0-0037089528
33. Özvegy-Laczka C., Köblös G., Sarkadi B., Váradi A., Single amino acid (482) variants of the ABCG2 multidrug transporter: major differences in transport capacity and substrate recognition. Biochimica et Biophysica Acta 2005 1668 1 53 63 2-s2.0-12844255054 10.1016/j.bbamem.2004.11. 005
34. Robey R. W., Honjo Y., Morisaki K., Nadjem T. A., Runge S., Risbood M., Poruchybsky M. S., Bates S. E., Mutations at amino-acid 482 in the ABCG2 gene affect substrate and antagonist specificity. British Journal of Cancer 2003 89 10 1971 1978 2-s2.0-0347382812 10.1038/sj.bjc.6601370
35. Polgar O., Robey R. W., Bates S. E., ABCG2: structure, function and role in drug response. Expert Opinion on Drug Metabolism and Toxicology 2008 4 1 1 5 2-s2.0-39049131573 10.1517/17425255.4.1.1
36. Pozza A., Perez-Victoria J. M., Sardo A., Ahmed-Belkacem A., Di Pietro A., Purification of breast cancer resistance protein ABCG2 and role of arginine-482. Cellular and Molecular Life Sciences 2006 63 16 1912 1922 2-s2.0-33747216808 10.1007/s00018-006-6159-7
37. Janvilisri T., Shahi S., Venter H., Balakrishnan L., Van Veen H. W., Arginine-482 is not essential for transport of antibiotics, primary bile acids and unconjugated sterols by the human breast cancer resistance protein (ABCG2). Biochemical Journal 2005 385 2 419 426 2-s2.0-12844280511 10.1042/BJ20040791
38. Ejendal K. F. K., Diop N. K., Schweiger L. C., Hrycyna C. A., The nature of amino acid 482 of human ABCG2 affects substrate transport and ATP hydrolysis but not substrate binding. Protein Science 2006 15 7 1597 1607 2-s2.0-33745726722 10.1110/ps.051998406
39. Eddabra L., Wenner T., El Btaouri H., Baranek T., Madoulet C., Cornillet-Lefebvre P., Hamid M., Arginine 482 to glycine mutation in ABCG2/BCRP increases etoposide transport and resistance to the drug in HEK-293 cells. Oncology Reports 2012 27 1 232 237 2-s2.0-84855288472 10.3892/or.2011.1468
40. Cervenak J., Andrikovics H., Özvegy-Laczka C., Tordai A., Német K., Váradi A., Sarkadi B., The role of the human ABCG2 multidrug transporter and its variants in cancer therapy and toxicology. Cancer Letters 2006 234 1 62 72 2-s2.0-33644811431 10.1016/j.canlet.2005.01.061
41. Hariharan R., Janakiraman A., Nilakantan R., Singh B., Varghese S., Landrum G., Schuffenhauer A., MultiMCS: a fast algorithm for the maximum common substructure problem on multiple molecules. Journal of Chemical Information and Modeling 2011 51 4 788 806 2-s2.0-79955388687 10.1021/ci100297y
42. Everitt B. S., Landau S., Leese M., Stahl D., Balding D. J., Cressie N. A. C., Fitzmaurice G. M., Goldstein H., Molenberghs G., Scott D. W., Smith A. F. M., Tsay R. S., Weisberg S., Optimization clustering techniques. Cluster Analysis 2011 5th Chichester, UK John Wiley & Sons
43. Varnek A., Baskin I., Machine learning methods for property prediction in chemoinformatics: quo vadis? Journal of Chemical Information and Modeling 2012 52 1413 1437
44. Ho T. K., The random subspace method for constructing decision forests. IEEE Transactions on Pattern Analysis and Machine Intelligence 1998 20 8 832 844 2-s2.0-0032139235 10.1109/34.709601
45. Talevi A., Bellera C. L., Di Ianni M., Duchowicz P. R., Bruno-Blanch L. E., Castro E. A., An integrated drug development approach applying topological descriptors. Current Computer-Aided Drug Design 2012 8 3 172 181
46. Triballeau N., Acher F., Brabet I., Pin J.-P., Bertrand H.-O., Virtual screening workflow development guided by the "receiver operating characteristic" curve approach. Application to high-throughput docking on metabotropic glutamate receptor subtype 4. Journal of Medicinal Chemistry 2005 48 7 2534 2547 2-s2.0-17144385534 10.1021/jm049092j
47. Hubbard R., Bayarri M. J., Confusion over measures of evidence (p's) versus errors (α 's) in classical statistical testing. American Statistician 2003 57 3 171 178 2-s2.0-0042074083
48. Truchon J.-F., Bayly C. I., Evaluating virtual screening methods: good and bad metrics for the "early recognition" problem. Journal of Chemical Information and Modeling 2007 47 2 488 508 2-s2.0-34247272948 10.1021/ci600426e
49. Dodd L. E., Pepe M. S., Partial AUC estimation and regression. Biometrics 2003 59 3 614 623 2-s2.0-0041833610 10.1111/1541-0420.00071
50. Kirchmair J., Markt P., Distinto S., Wolber G., Langer T., Evaluation of the performance of 3D virtual screening protocols: RMSD comparisons, enrichment assessments, and decoy selection-what can we learn from earlier mistakes? Journal of Computer-Aided Molecular Design 2008 22 3-4 213 228 2-s2.0-41349106585 10.1007/s10822-007-9163-6
51. Zhao W., Hevener K. E., White S. W., Lee R. E., Boyett J. M., A statistical framework to evaluate virtual screening. BMC Bioinformatics 2009 10, article 225 2-s2.0-68949158347 10.1186/1471-2105-10-225
52. Bamber D., The area above the ordinal dominance graph and the area below the receiver operating characteristic graph. Journal of Mathematical Psychology 1975 12 4 387 415 2-s2.0-49549139345
53. Hanley J. A., McNeil B. J., The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 1982 143 1 29 36 2-s2.0-0020083498
54. Pesce L. L., Papaioannu J., Metz C. E., ROC-kit software 2009. http://metz-roc.uchicago.edu/MetzROC/software
55. Robin X., Turck N., Hainard A., Tiberti N., Lisacek F., Sanchez J.-C., Müller M., pROC: an open-source package for R and S+ to analyze and compare ROC curves. BMC Bioinformatics 2011 12, article 77 2-s2.0-79952709519 10.1186/1471-2105-12-77
56. Pepe M. S., The Statistical Evaluation of Medical Tests for Classification and Prediction 2004 Oxford, UK Oxford University Press
57. Pesce L. L., Metz C. E., Berbaum K. S., On the convexity of ROC curves estimated from radiological test results. Academic Radiology 2010 17 8 960 968.e4 2-s2.0-77954178516 10.1016/j.acra.2010.04.001
58. DeLong E. R., DeLong D. M., Clarke-Pearson D. L., Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 1988 44 3 837 845 2-s2.0-0023710206
59. Carpenter J., Bithell J., Bootstrap confidence intervals: when, which, what? A practical guide for medical statisticians. Statistics in Medicine 2000 19 9 1141 1164
60. Kairys V., Fernandes M. X., Gilson M. K., Screening drug-like compounds by docking to homology models: a systematic study. Journal of Chemical Information and Modeling 2006 46 1 365 379 2-s2.0-33244475355 10.1021/ci050238c
61. Kearsley S. K., Sallamack S., Fluder E. M., Andose J. D., Mosley R. T., Sheridan R. P., Chemical similarity using physiochemical property descriptors. Journal of Chemical Information and Computer Sciences 1996 36 1 118 127 2-s2.0-0001577643
62. Sheridan R. P., Singh S. B., Fluder E. M., Kearsley S. K., Protocols for bridging the peptide to nonpeptide gap in topological similarity searches. Journal of Chemical Information and Computer Sciences 2001 41 3-6 1395 1406 2-s2.0-0035438401
63. Yabuuchi H., Niijima S., Takematsu H., Ida T., Hirokawa T., Hara T., Ogawa T., Minowa Y., Tsujimoto G., Okuno Y., Analysis of multiple compound-protein interactions reveals novel bioactive molecules. Molecular Systems Biology 2011 7, article 472 2-s2.0-79952345084 10.1038/msb.2011.5
64. Tetko I. V., Neural network studies. 4. Introduction to associative neural networks. Journal of Chemical Information and Computer Sciences 2002 42 3 717 728 2-s2.0-0036557849 10.1021/ci010379o
65. Tetko I. V., Tanchuk V. Y., Chentsova N. P., Antonenko S. V., Poda G. I., Kukhar V. P., Luik A. I., HIV-1 reverse transcriptase inhibitor design using artificial neural networks. Journal of Medicinal Chemistry 1994 37 16 2520 2526 2-s2.0-0028106835
66. Artemenko N. V., Baskin I. I., Palyulin V. A., Zefirov N. S., Artificial neural network and fragmental approach in prediction of physicochemical properties of organic compounds. Russian Chemical Bulletin 2003 52 1 20 29 2-s2.0-0037287399 10.1023/A:1022467508832
67. Zhokhova N. I., Baskin I. I., Palyulin V. A., Zefirov A. N., Zefirov N. S., Fragmental descriptors with labeled atoms and their application in QSAR/QSPR studies. Doklady Chemistry 2007 417 2 282 284 2-s2.0-37649009464 10.1134/S0012500807120026
68. Zhu H., Tropsha A., Fourches D., Varnek A., Papa E., Gramatical P., Öberg T., Dao P., Cherkasov A., Tetko I. V., Combinatorial QSAR modeling of chemical toxicants tested against Tetrahymena pyriformis. Journal of Chemical Information and Modeling 2008 48 4 766 784 2-s2.0-44449173096 10.1021/ci700443v
69. Varnek A., Fourches D., Horvath D., Klimchuk O., Gaudin C., Vayer P., Solov'ev V., Hoonakker F., Tetko I. V., Marcou G., ISIDA: platform for virtual screening based on fragment and pharmacophoric descriptors. Current Computer-Aided Drug Design 2008 4 3 191 198 2-s2.0-54749103171 10.2174/157340908785747465